Novo Nordisk (ADR) (NVO)
Develops GLP-1 and insulin medicines for diabetes, obesity and rare diseases.
Something off on this page? Send us feedback.
Sells GLP-1 medicines and insulin for diabetes and obesity, with a smaller rare-disease business in haemophilia and growth disorders. Protein-drug and injection-device expertise supports injectable and oral formats, while access depends on regulation, reimbursement and manufacturing capacity.
Develops and markets GLP-1 medicines and insulin for diabetes and obesity, supported by injection devices and newer oral formats. Rare Disease adds haemophilia and growth-hormone therapies as a smaller, separately reported business.
Operations span the United States and international markets. A century of protein-medicine development and self-administration devices underpins the transition from insulin into GLP-1 products for both diabetes and weight management.
Commercial access depends on regulatory approval, compliant safety communication, payer coverage and adequate manufacturing capacity. Periodic supply constraints have persisted for some products even as filling capacity expanded, while compounded semaglutide and rival obesity medicines shape competition. A Danish foundation-linked shareholder retains decisive voting control through the dual-class structure.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 11, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $42 | Target: $40 |
| Aug 27, 2026 | Deutsche Bank | Downgrade | ||
| Aug 12, 2026 | Berenberg Bank | Target | Target: — | Target: $47 |
| Aug 6, 2026 | BMO Capital | Reiterate | Rating: —Target: $45 | Target: $47 |
| Jun 19, 2026 | Nordea | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $6.89B · Total debt $21.47B · Total assets $91.17B · Shareholders' equity $33.91B
- Revenue
- $12.03B
- Operating income
- $4.15B
- Net income
- $3.22B
Reported in DKK, converted at the latest exchange rate
HistoryDividendAnnual yield
| Institutions | 7.34% | 327.95M ADS | |
|---|---|---|---|
| 1,454 holders · as of Jun 30, 2026 | |||
| Other | 92.66% | 4.14B ADS | |
| remainder | |||
4.47B ADS as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Dodge & CoxInstitution | 0.46% | 20.40M ADS | as of Jun 30, 2026 |
Loomis Sayles & Co L PInstitution | 0.42% | 18.59M ADS | as of Jun 30, 2026 |
Franklin Resources IncInstitution | 0.29% | 13.04M ADS | as of Jun 30, 2026 |
Price T Rowe Associates Inc /MD/Institution | 0.26% | 11.70M ADS | as of Jun 30, 2026 |
Morgan StanleyInstitution | 0.26% | 11.66M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Eli Lilly
Dominant incretin rival across obesity and type 2 diabetes
- Sanofi (ADR)
Direct overlap in basal insulin and haemophilia medicines
- Pfizer
Focused overlap in haemophilia and growth hormone therapy
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Novo Nordisk (ADR) | $39.49 | −0.75% | $176.83B | 9.9 | 16.3 | 3.5 | +1.3% |
| Eli Lilly | $1,150.74 | −1.15% | $1.10T | 39.1 | 28.5 | 13.8 | +47.7% |
| Sanofi (ADR) | $42.43 | −0.22% | $102.05B | 75.6 | — | 1.8 | +11.2% |
| Pfizer | $27.72 | −0.18% | $158.10B | 36.7 | 9.9 | 2.5 | +2.6% |
| Median | 39.1 | 19.2 | 2.5 | +11.2% |